Donepezil for Cognitive Impairment in Parkinson's Disease: A Randomised Controlled Study
JNNP 72:708-712, Aarsland,D.,et al, 2002
Cerebellar Ataxia With Anti-Glutamic Acid Decarboxylase Antibodies
Arch Neurol 58:225-230, Honorat,J.,et al, 2001
Sensory Guillain-Barre Syndrome
Neurol 56:82-86, Oh,S.J.,et al, 2001
14-3-3 Protein Cerebrspinal Fluid Detection in Human Growth Hormone-Treated Creutzfeldt-Jakob Disease Patients
Ann Neurol 49:257-260, Brandel,J.,et al, 2001
Clinical Diagnosis of Cerebral Amyloid Angiopathy: Validation of the Boston Criteria
Neurol 56:537-539, Knudsen,K.A.,et al, 2001
Use of Specialized Coagulation Testing in the Evaluation of Patients with Acute Ischemic Stroke
Neurol 56:624-627, Bushnell,C.,et al, 2001
Clinicopath Conf, Lymphoblastic Lymphoma
NEJM 344:832-839, Case 8-2001, 2001
Isolated Demyelinating Syndromes: Comparison of CSF Oligoclonal Bands and Different MR Imaging Criteria to Predict Conversion to CDMS
Mult Scler 7:359-363, Tintore,M.,et al, 2001
CSF Oligoclonal Bands in MS Include Antibodies Against Chlamydophila Antigens
Neurol 56:1168-1176,1126,1128,1130, Yao,S.,et al, 2001
Neurodegenerative Diseases and Prions
NEJM 344:1516-1526,1548, Prusiner,S.B., 2001
C-Reactive Protein in Ischemic Stroke
Stroke 32:917-924, De Napoli,M.,et al, 2001
Clinical and Neuroradiologic Features of Acute Disseminated Encephalomyelitis in Children
Neurol 56:1308-1312,1257, Hynson,J.L.,et al, 2001
Effect of Early Interferon Treatment on Conversion to Definite Multiple Sclerosis: A Randomised Study
Lancet 357:1576-1582,1547, Comi,G.,et al, 2001
Acute Disseminated Encephalomyelitis
Neurol 56:1313-1318,1257, Schwarz,S.,et al, 2001
Fulminant Liver Failure During Interferon Beta Treatment of Multiple Sclerosis
Neurol 56:1416, Yoshida,E.M.,et al, 2001
Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1496-1504, Secondary Progressive Efficacy Clinical Trial of R, 2001
Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1505-1513, Li,D.K.B.,et al, 2001
CSF Detection of the 14-3-3 Protein in Unselected Patients with Dementia
Neurol 56:1528-1533, Burkhard,P.R.,et al, 2001
Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
Ann Neurol 50:121-127, McDonald,W.I.,et al, 2001
PRISMS-4: Long-Term Efficacy of Interferon-B-1a in Relapsing MS
Neurol 56:1628-1636,1620, The PRISMS Study Group, 2001
Cerebral Amyloid Angiopathy Presenting as Nonhemorrhagic Diffuse Encephalopathy: Neuropathologic and Neuroradiologic Manifestations in One Case
AJNR 22:1072-1076, Caulo,M.,et al, 2001
Use of 14-3-3 and Other Brain-specific Proteins in CSF in the Diagnosis of Variant Creutzfeldt-Jakob Disease
JNNP 70:744-748, Green,A.J.E.,et al, 2001
Measurement of Antibodies to Interferon Beta in Patients With Multiple Sclerosis
Arch Neurol 58:1299-1300,1301, Pachner,A.R., 2001
The Significance of Neutralizing Antibodies in Patients With Multiple Sclerosis Treated With Interferon Beta
Arch Neurol 58:1297-1298,1301, Rice,G., 2001
Asystole Induced by Edrophonium Following Beta Blockade
Neurol 57:739, Okun,M.S.,et al, 2001
Quantitation of 14-3-3 and Neurol-Specific Enolase Proteins in CSF in Creutzfeldt-Jakob Disease
Neurol 57:728-730, Aksamit,A.L.,et al, 2001
14-3-3 Protein in the CSF as Prognostic Marker in Early Multiple Sclerosis
Neurol 57:722-724, Martinez-Yelamos,A.,et al, 2001
Nonpoliovirus Poliomyelitis Simulating Guillain-Barre Syndrome
Arch Neurol 58:1460-1464, Gorson,K.C.&Ropper,A.H., 2001
Essential Tremor
NEJM 345:887-891, Louis,E.D., 2001
The Neurologic Complications of Scleromyxedema
Medicine 80:313-319, Berger,J.R.,et al, 2001
Plasma Concentration of C-Reactive Protein and Risk of Ischemic Stroke and Transient Ischemic Attack
Stroke 32:2575-2579, Rost,N.S.,et al, 2001
C-Reactive Protein Levels and Viable Chlamydia pneumoniae in Carotid Artery Atherosclerosis
Stroke 32:2748-2752, Claiborne Johnston,S.,et al, 2001
Oligoclonal Band Number as a Marker for Prognosis in Multiple Sclerosis
Arch Neurol 58:2044-2045, Avasarala,J.R.,et al, 2001
The Effect of IFNB-1b on the Evolution of Enhancing Lesions in Secondary Progressive MS
Neurol 57:2185-2190, Brex,P.A.,et al, 2001
Effect of Interferon B-1b in MS, Assessment of Annual Accumulation of PD/T2 Activity on MRI
Neurol 54:200-206, Zhao,G.J.,et al, 2000
Diagnosis and Treatment of Intravascular Lymphomatosis
ArchNeurol 57:374-377, Baumann,T.P.,et al, 2000
Progressive Necrotic Myelopathy
ArchNeurol 57:355-361, Katz,J.D. & Ropper,A.H., 2000
Vitamin E and Beta Carotene Supplementation in High Risk for Stroke
Arch Neurol 57:1503-1509, Leppala,J.M.,et al, 2000
Syndrome of Cerebral Spinal Fluid Hypovolemia
Neurol 55:1321-1327, Chung,S.J.,et al, 2000
Misleading Results With the 14-3-3 Assay for the Diagnosis of Creutzfeldt-Jakob Disease
Neurol 55:1396-1397, Chapman,T.,et al, 2000
Dementia with Lewy Bodies in a Neuropathologic Series of Suspected Creutzfeldt-Jakob Disease
Neurol 55:1401-1404, Haik,S.,et al, 2000
Vasovagal Syncope
Ann Int Med 133:714-725, Fenton,A.M.,et al, 2000
Warfarin-Associated Hemorrhage and Cerebral Amyloid Angiopathy
Neurol 55:947-951, Rosand,J.,et al, 2000
Amyloidosis Presenting with Intractable Epistaxis and Multiple Cranial Neuropathies
Neurol 55:1755-1756, Van Gerpen,J.A.,et al, 2000
Diagnostic Testing for Coagulopathies in Patients With Ischemic Stroke
Stroke 31:3067-3078, Bushnell,C.D. & Goldstein,L.B., 2000
Protein C Deficiency Related to Valproic Acid Therapy: A Possible Association with Childhood Stroke
J Pediatr 137:714-718, Gruppo,R.,et al, 2000
Verapamil in the Prophylaxis of Episodic Cluster Headache:A Double-Blind Study Versus Placebo
Neurol 54:1382-1385, Leone,M.,et al, 2000
Primary Neurosarcoidosis:A Diagnostic and Therapeutic Challenge
The Neurologist 6:126-133, Nikhar,N.K.,et al, 2000
Cardiac Dysfunction in Neuromuscular Diseases
The Neurologist 6:67-82, Pourmand,R., 2000
Aspirin-Associated Intracerebral Hemorrhage
Neurol 54:2298-2301, Wong,K.S.,et al, 2000